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well-defined and diverse PBA patient population, showing statistically significant 
improvements in a range of validated clinical and HRQoL outcomes relevant for 
the treatment of PBA. CONCLUSIONS: The evidence base for off-label agents used 
for treatment of PBA is limited, relying on small often uncontrolled studies show-
ing ill-defined treatment effects and little or no safety tracking. DM/Q is the only 
treatment for PBA that has demonstrated efficacy in well-conducted clinical trials 
in patients with varied neurological disorders.
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OBJECTIVES: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing-remitting MS. Here we report the key efficacy, safety, and post hoc analy-
ses from the randomized, placebo-controlled phase 3 trials TEMSO (NCT00134563) 
and TOWER (NCT00751881). METHODS: In TEMSO/TOWER, a total of 1088/1169 
patients with relapsing MS were randomized (1:1:1) to once-daily teriflunomide 14 
mg, teriflunomide 7 mg, or placebo. Treatment duration was 108 weeks (TEMSO) or 
variable, based on time of enrollment (TOWER; 48–152 weeks, ending 48 weeks after 
last patient randomized). Primary and key secondary endpoints were annualized 
relapse rate (ARR) and disability progression confirmed for 12 weeks. Additional 
endpoints included safety and tolerability. Post hoc analyses examined the effect 
of teriflunomide on 5 severe relapse outcomes: (A) relapses with sequelae defined 
by increase in Expanded Disability Status Scale score/Functional Score 30 days 
postrelapse; (B) relapses with investigator-defined sequelae; (C) severe relapses by 
Panitch definition; (D) relapses leading to hospitalization; and (E) relapses requir-
ing treatment with intravenous corticosteroids. RESULTS: In TEMSO/TOWER, 
teriflunomide 14 mg significantly reduced both ARR and disability progression vs 
placebo. Teriflunomide 7 mg significantly reduced ARR but not disability progres-
sion. Teriflunomide 14 mg significantly reduced annualized rates of severe relapse 
outcomes compared with placebo in TEMSO/TOWER by: (A) 36.2% (P= 0.0011)/36.6% 
(P= 0.0021); (B) 52.6% (P< 0.0001)/53.5% (P= 0.0004); (C) 38.5% (P= 0.0286)/52.5% 
(P= 0.0015); (D) 59.3% (P< 0.0001)/33.6% (P= 0.0155); and (E) 33.7% (P= 0.0003)/35.7% 
(P= 0.0002). Teriflunomide 7 mg also reduced annualized rates of severe relapses, 
although not significantly in all definitions. Both teriflunomide doses showed simi-
lar safety profiles across the 2 studies. CONCLUSIONS: Teriflunomide 14 mg has 
shown consistent and significant positive effects on ARR and disability progression 
in 2 phase 3 studies. Teriflunomide also reduces severe relapses as measured by 
various relapse definitions, which may reduce relapse-related healthcare costs and 
improve patients’ quality of life.
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OBJECTIVES: Multiple sclerosis (MS) disease progression is measured by the 
Expanded Disability Status Scale (EDSS). UK MS clinical guidelines1recommend that 
patients discontinue treatment with disease modifying therapies (DMTs) on reach-
ing EDSS ≥ 7.0, or experiencing non-relapsing secondary progressive MS (SPMS). This 
study derived the time for patients to reach EDSS ≥ 7.0 or SPMS from EDSS 4.0 or 
5.0, for patients treated with delayed-release dimethyl fumarate 240mg (DMF; also 
known as gastro-resistant DMF), or no DMT treatment. METHODS: The time taken 
to reach relapsing-remitting MS (RRMS) EDSS ≥ 7.0, or SPMS (any EDSS state) from 
EDSS 4.0 or 5.0 was estimated from transition probability matrices using algebraic 
techniques from Mandel 20072: the time to EDSS ≥ 7.0 or SPMS was derived for each 
matrix (DMF, untreated) by using matrix multiplication to estimate the proportion of 
patients who had reached these states over time. The transition matrix for untreated 
patients was derived using placebo arm data from clinical trials3,4(for RRMS popula-
tion) and London Ontario dataset (for transitions from RRMS to SPMS). The transition 
matrix for DMF was estimated by applying treatment effect on disability progression 
(sourced from a mixed treatment comparison), to the probability of progressing in 
the untreated matrix. Probabilistic sensitivity analysis was conducted to estimate 
95% confidence intervals (CIs). RESULTS: The time for progression from EDSS 4.0 
to ≥ 7.0 or SPMS was 8.53 years (95% CI: 7.05-10.25) for patients treated with DMF 
and 5.90 years (95% CI: 5.59-6.24) for untreated patients. The time from EDSS 5.0 to 
≥ 7.0 or SPMS was 5.28 years (95% CI: 4.32-6.37) for patients treated with DMF and 
3.64 years (95% CI: 3.34-3.96) for untreated patients. CONCLUSIONS: Our analysis 
showed that DMF therapy was associated with a longer time interval between EDSS 
4.0 or 5.0 and progression to EDSS ≥ 7.0 or SPMS relative to no DMT treatment.
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OBJECTIVES: Teriflunomide and dimethyl fumarate (DMF), oral therapies for 
relapsing-remitting MS, have demonstrated efficacy in clinical trials on magnetic 
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OBJECTIVES: IPX066, an extended-release capsule formulation of carbidopa-levo-
dopa (CD-LD), is designed to produce a rapid increase in plasma levodopa concen-
trations similar to immediate-release CD-LD (IR), but with sustained plasma levels 
allowing dosing every 6 hours. This post hoc analysis investigated whether baseline 
Parkinson’s disease (PD) severity influenced the patient reported efficacy of IPX066 
vs. IR in advanced PD patients. METHODS: IPX066 was evaluated in a randomized, 
double-blind, Phase 3 study vs. IR CD-LD for 13 weeks (N= 393). Patients were split 
into subgroups of higher and lower disease severity based on median baseline “off” 
time (5.67 hr) and Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II+III 
(score: 32). Patient Global Impression (PGI), and the change from baseline in “off” 
time and “on” time with troublesome dyskinesia by PD diary were analyzed for 
each subgroup. RESULTS: IPX066 significantly improved PGI (P< .0001) and “off” time 
(P< .0001) compared with IR CD-LD in the overall randomized population. IPX066 
significantly improved PGI scores compared with IR CD-LD in both higher severity 
subgroups (P< .001) and lower severity subgroups (P< .02). Numerical improvements 
from baseline in “off” time were seen with IPX066 vs. IR CD-LD in each disease sever-
ity subgroup. The improvements in “off” time were significantly greater for IPX066 
vs. IR CD-LD in the higher severity “off” (P< .0001) and in both the higher (P= .02) and 
lower severity (P= .0001) UPDRS subgroups. The improvement by IPX066 compared 
to IR CD-LD in the lower severity “off” subgroup did not reach significance (P= .11), 
possibly due to a floor effect. IPX066 did not significantly worsen “on” time with trou-
blesome dyskinesia compared to IR CD-LD in any subgroup (P> .14). CONCLUSIONS: 
Advanced PD patients reported higher global impression of change and greater 
improvements in “off” time without worsening troublesome dyskinesia after treat-
ment with IPX066 compared with IR CD-LD, regardless of disease severity subgroup.
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OBJECTIVES: We performed a systematic review of randomized controlled tri-
als (RCTs) to estimate the efficacy of melatonin versus placebo or other hypnotic 
agents on the improvement of sleep quality and quantity in patients with primary 
insomnia. METHODS: We searched the published literatures in eight electronic 
databases, including Ovid-Medline, EMBASE, the Cochrane Library, and five Korean 
databases through October 2014. We included articles comparing efficacy for sleep 
between melatonin and placebo or other hypnotics among primary insomnia 
patients. The quality of studies was evaluated by using the Cochrane’s risk of bias. 
The mean difference (MD) or standardized mean difference (SMD) was calculated 
using the random-effects method for each study outcome. To assess heterogene-
ity of inter-trial, we used the I2-statistic. Subgroup-analyses were performed by 
assessment tools, study designs, ages and dosage of melatonin. Funnel plots were 
used to assess publication bias. RESULTS: Eighteen RCTs were identified and the 
comparison groups of all included trials were placebo. Compared with placebo, 
melatonin significantly reduced sleep onset latency (MD: -6.58 min [95% confidential 
interval (CI): -9.75 to -3.41], p < 0.0001), and increased total sleep time (MD: 20.56 
min [95% CI: 4.70 to 36.41], p = 0.01) and sleep efficiency (MD: 3.47% [95% CI: 0.37 to 
6.58], p = 0.03). Sleep quality was also improved (SMD: 0.22 [95% CI: 0.03 to 0.40], p = 
0.02) in melatonin group but this result was concluded based on a small number of 
studies. In subgroup-analyses for each outcome, there was no clinically remarkable 
finding. We did not find any evidence of statistical heterogeneity and publication 
bias. CONCLUSIONS: Melatonin showed to be effective for sleep in comparison 
with placebo, thus can be an effective option for the treatment of insomnia. Further 
studies are needed to conclude safety profiles, economic usefulness and tolerance 
of melatonin.
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OBJECTIVES: PBA is a neurologic disorder characterized by involuntary, uncontrol-
lable laughing and/or crying episodes that are often incongruent with the patient’s 
internal emotional state; PBA has also been called pathological laughing/crying, 
emotionalism, etc. Until FDA approval of dextromethorphan/quinidine (DM/Q) in 
2010, multiple agents including antidepressants, antipsychotics, dopamine ago-
nists and sedatives were used off-label for the management of PBA symptoms. 
We conducted a systematic review of therapies (licensed and unlicensed) for PBA 
symptoms to evaluate their relative clinical effectiveness METHODS: Databases: 
Medline, Medline in process, Embase and the Cochrane central register of con-
trolled trials; conference abstracts were searched in Embase. Study type: RCTs and 
non-RCTs in adult patients with PBA/PBA-like symptoms (pathological laughing/
crying, emotionalism, etc). Interventions: DM/Q, antidepressants, antipsychotics, 
dextromethorphan and quinidine alone. Outcome measures: change from baseline 
in various measures of PBA/emotionalism symptoms or symptom burden (NPI, 
SF-36, PRS scores and the caregiver strain index (CSI)). RESULTS: Nine RCTs and 
three observational studies were included. Among off-label drugs, six RCTs of 3 
SSRIs and 2 TCAs showed improvements in disparate PBA symptom measures, only 
1 used a validated symptom measure. These studies were small (N= 6-28) using 
mostly stroke patients. They were heterogeneous on how they defined/diagnosed 
PBA and varied in duration (1.4-24 weeks). As such, no formal evidence synthesis 
was possible. Three RCTs and one open label trial investigating DM/Q included a 
